Pregnancy and Baby Outcomes in Women Aged 18 to 45 With Inflammatory Bowel Disease Taking Biologic or Immunosuppressant Medicines

What this Trial Is About

Researchers are conducting a national prospective study to evaluate pregnancy and newborn outcomes in women with Inflammatory Bowel Disease IBD. The study focuses on how medication use and disease activity affect pregnancy outcomes up to 18 years after birth. It involves multiple centers across the United States, including the University of California San Francisco and 30 other sites part of the CCFA Clinical Alliance. Participants are pregnant women diagnosed with IBD who are currently taking biologic medicines or immunosuppressants. The study tracks these women and their children over many years to understand the impact of these treatments and disease activity on pregnancy and child development. Women in the study will be observed during pregnancy and through long-term follow-up of their children. Researchers will use tools like the Ages and Stages Questionnaire ASQ-3 to measure developmental delays in children at 12, 24, 36, and 48 months. Additional data will be collected on pregnancy outcomes and medication exposure. The total participation may extend up to 18 years from the childs birth, with ongoing monitoring for developmental and health outcomes.

A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women With Inflammatory Bowel Disease